Does anyone have experience with Linear Discriminant Analysis (LDA) to distinguish mutant and control imaging-based phenotypes from each other? Can combinations of subtle differences lead to a biological meaningful distinction?

Lots of data is of course needed for LDA model development. How robust are those models when a large total number of images is present, but only a small number of images are compared directly i.e. in a high-throughput screening? For example a single drug-treated well (of which many exist) would be compared to a small number of DMSO treated wells.

Is anyone willing to share some LDA experiences concerning stability and test-ability of biological usefulness (for example validation of the LDA model with positive/negative control compounds)?

Thanks!

More Johannes Wilbertz's questions See All
Similar questions and discussions